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Open pilot study of gabapentin versus trazodone to treat 














Alcohol-dependent outpatients with persisting insomnia were treated with either gabapentin
or trazodone. Patients were assessed at baseline and after 4–6 weeks on medication using the
Sleep Problems Questionnaire (SPQ). Of 55 cases initially treated, 9% dropped out due to

















57 mg) at bedtime.
Both groups improved significantly on the SPQ but the gabapentin group improved significantly








Insomnia is common and may increase the risk of
relapse in treated alcoholics, even after controlling




 Unfortunately the abuse
potential of commonly used sedative–hypnotic drugs





and sedating antidepressants have recently emerged
as possibly effective medications for treating patients




Trazodone is a sedating antidepressant that has been













 have improved sleep on trazodone, presumably
due to its serotonergic activity. Gabapentin is an anti-
epileptic drug that has also been used in the treatment
of alcohol-related disorders because of its anticon-














For these reasons we compared trazodone versus





Of 71 alcohol-dependent outpatients consecutively
referred to an addiction psychiatrist for complaints of
insomnia, 55 met study criteria and received either
gabapentin or trazodone after giving written informed
consent. To qualify, patients (i) met 
 
Diagnostic and
Statistical Manual of Mental Disorders
 
 (4th edn; DSM-
IV) criteria for alcohol dependence as determined by
the psychiatric evaluation; (ii) had insomnia that per-
sisted despite 4 or more weeks of abstinence as verified
by breath tests and urine drug screens; (iii) did not
have insomnia due to substance intoxication or with-
drawal, medications, or an unstable mental or medical
disorder (other than alcohol dependence); and (iv) had
normal serum creatinine levels and liver transaminases
(because gabapentin is eliminated by the kidney and
trazodone is metabolized in the liver). Patients were
informed that gabapentin and trazodone were alterna-
tive agents for treating insomnia without the worry of
dependence associated with other sleeping pills. After
discussing the potential side-effects and benefits of
each medication, the patient and psychiatrist made a
collaborative decision about which medication to use,
as ordinarily occurs in clinical practice.
Gabapentin-treated patients were started on 300 mg
by mouth at bedtime, and increased as needed by
300 mg each night to a maximum of 1800 mg as a single
bedtime dose. Trazodone-treated patients were started
at 25 mg by mouth at bedtime, and increased as needed
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by 25 mg every two nights to a maximum of 300 mg as
a single bedtime dose. Patients were instructed to take
their medication 30–60 min before bedtime.





to assess the severity of insomnia at baseline (t1) and
4–6 weeks later at follow up (t2). The SPQ is a four-
item, self-administered measure of the past 1 month.
Initial insomnia, middle insomnia, terminal insomnia,
and feeling tired and worn out upon awakening are
each assessed by one item, which have scores ranging
from 0 (no disturbance) to 5 (daily disturbance) for a
maximum total score of 20. A previous report indicated
that the SPQ was sensitive to improvement in sleep







Of the 55 patients who consented to take medication,
two (11%) of 18 patients stopped trazodone and three
(8%) of 37 patients stopped gabapentin after the first
dose due to excessive sleepiness or drowsiness the next
day. These five patients were not included in any fur-
ther analyses. Of the remaining 50 patients, 16 received









at bedtime (range 50–300 mg), and 34 received gabap-




418 mg at bed-
time (range: 300–1800 mg). The two medication groups
differed in sample size because the choice of medica-
tion for each patient resulted from a collaborative
patient–physician discussion rather than random
assignment.
The trazodone and gabapentin groups did not differ













years), gender (62% female), race (84% Caucasian,
12% African–American, 4% other), or employment
(66% employed), although there was a lower percent-
age of men in the trazodone group versus the gabap-























Sixty-four percent of the sample had a diagnosis of
nicotine dependence and 66% had at least one other
substance dependence disorder without significant dif-
ferences between groups. Comorbid but stable mood
or anxiety disorders were present in 14 (88%) of the
trazodone-treated patients and 29 (85%) of the gaba-
pentin-treated patients.
As shown in Fig. 1, total SPQ scores did not differ










groups showed significant improvement in sleep from

































































A linear regression analysis demonstrated that medi-
cation group significantly predicted overall SPQ
change scores after controlling for age, gender, and
pretreatment total sleep score.
The SPQ individual item scores were dichotomized
because of skewed distributions. Patients scoring from
3 to 5 on an individual item were classified as having
the symptom because it occurred more than 7 days in
the past 31 days, whereas patients scoring from 0 to 2
were classified as not having the symptom. Results
are shown in Table 1. Patients treated with trazodone




Sleep problems questionnaire (SPQ) scores















) and follow up for
the trazodone (a) and gabapentin (b) groups, and between

































Sleep characteristics at baseline (t1) and follow up






















Initial insomnia at t1 (%) 100 76.5*
Initial insomnia at t2 (%) 37.5 8.8*
Middle insomnia at t1 (%) 81.3 85.3
Middle insomnia at t2 (%) 37.5 23.5
Terminal insomnia at t1 (%) 56.3 76.5
Terminal insomnia at t2 (%) 25.0 14.7
Tired & worn out upon
awakening at t1 (%)
87.5 85.3
Tired & worn out upon


















Variables were analyzed by Fisher’s exact test. All tests
were two-tailed.
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0.022). The two groups
did not differ at baseline in terms of middle insomnia
(84%), terminal insomnia (70%), or feeling tired and
worn out upon awakening (86%). At follow up, how-
ever, the trazodone group was more likely than the




















Two patients from each medication group admitted





After at least 4 weeks of abstinence, alcoholic patients
with persistent insomnia reported significant sleep
improvement during treatment with either gabapentin
or trazodone. Although the overall sleep of each med-
ication group improved significantly over time, patients
who received gabapentin improved significantly more
than did patients who received trazodone. At follow
up, gabapentin-treated patients were less likely than
trazodone-treated patients to have initial insomnia and
to awaken in the morning feeling tired and worn out.
Both gabapentin and trazodone were well tolerated as
indicated by low dropout rates that did not differ sig-
nificantly between the two groups. All dropouts
occurred after the first dose of medication because of
morning drowsiness.
These findings must be viewed as preliminary.
Patients were not randomized, no placebo control
group was used, and neither patients nor psychiatrist
was blinded to medication. Other limitations include
the small sample size, brief follow-up period, and lack
of polysomnographic measures to complement subjec-
tive reports of insomnia and to rule out other sleep
disorders. It is also not known whether the dosages of
the two medications were equivalent. Finally, the study
was not able to determine the effect of medication on
relapse rates.
Despite its limitations, this is the first study to com-
pare gabapentin and trazodone for treating insomnia
in alcohol-dependent patients. Double-blind, random-
ized controlled trials are indicated to investigate the
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